Page 1099 - Clinical Immunology_ Principles and Practice ( PDFDrive )

ChaPTEr 78 Lymphoid Leukemias 1063

REFERENCES children and young adults: a phase 1 dose-escalation trial. Lancet
2015;385:517–28.
1. Pui CH, Yang JJ, Hunger SP, et al. Childhood Acute Lymphoblastic 22. Zent CS, Kyasa MJ, Evans R, et al. Chronic lymphocytic leukemia
Leukemia: Progress Through Collaboration. J Clin Oncol incidence is substantially higher than estimated from tumor registry data.
2015;33:2938–48. Cancer 2001;92:1325–30.
2. Greaves M. Infection, immune responses and the aetiology of childhood 23. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl
leukaemia. Nat Rev Cancer 2006;6:193–203. J Med 2005;352:804–15.
3. Kuehn HS, Boisson B, Cunningham-Rundles C, et al. Loss of B Cells in 24. Strati P, Shanafelt TD. Monoclonal B-cell lymphocytosis and early-stage
Patients with Heterozygous Mutations in IKAROS. N Engl J Med chronic lymphocytic leukemia: diagnosis, natural history, and risk
2016;374:1032–43. stratification. Blood 2015;126:454–62.
4. Noetzli L, Lo RW, Lee-Sherick AB, et al. Germline mutations in ETV6 are 25. Goldin LR, Bjorkholm M, Kristinsson SY, et al. Elevated risk of chronic
associated with thrombocytopenia, red cell macrocytosis and lymphocytic leukemia and other indolent non-Hodgkin’s lymphomas
predisposition to lymphoblastic leukemia. Nat Genet 2015;47:535–8. among relatives of patients with chronic lymphocytic leukemia.
5. Linden T, Schnittger S, Groll AH, et al. Childhood B-cell precursor acute Haematologica 2009;94:647–53.
lymphoblastic leukaemia in a patient with familial thrombocytopenia and 26. Ten Hacken E, Burger JA. Microenvironment interactions and B-cell
RUNX1 mutation. Br J Haematol 2010;151:528–30. receptor signaling in Chronic Lymphocytic Leukemia: Implications for
6. Hyde RK, Liu PP. Germline PAX5 mutations and B cell leukemia. Nat disease pathogenesis and treatment. Biochim Biophys Acta
Genet 2013;45:1104–5. 2015;1863:401–13.
7. Martin-Lorenzo A, Hauer J, Vicente-Duenas C, et al. Infection Exposure 27. Herishanu Y, Perez-Galan P, Liu D, et al. The lymph node
is a Causal Factor in B-cell Precursor Acute Lymphoblastic Leukemia as a microenvironment promotes B-cell receptor signaling, NF-kappaB
Result of Pax5-Inherited Susceptibility. Cancer Discov 2015;5:1328–43. activation, and tumor proliferation in chronic lymphocytic leukemia.
8. Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor Blood 2011;117:563–74.
leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. 28. Messmer BT, Messmer D, Allen SL, et al. In vivo measurements document
Lancet Oncol 2009;10:147–56. the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J
9. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Clin Invest 2005;115:755–64.
Health Organization classification of myeloid neoplasms and acute 29. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic
leukemia. Blood 2016;127:2391–405. lymphocytic leukemia. Blood 1975;46:219–34.
10. Tal N, Shochat C, Geron I, et al. Interleukin 7 and thymic stromal 30. Binet JL, Lepoprier M, Dighiero G, et al. A clinical staging system for
lymphopoietin: from immunity to leukemia. Cell Mol Life Sci chronic lymphocytic leukemia: prognostic significance. Cancer
2014;71:365–78. 1977;40:855–64.
11. Buchner M, Swaminathan S, Chen Z, et al. Mechanisms of pre-B-cell 31. Nabhan C, Raca G, Wang YL. Predicting Prognosis in Chronic
receptor checkpoint control and its oncogenic subversion in acute Lymphocytic Leukemia in the Contemporary Era. JAMA Oncol
lymphoblastic leukemia. Immunol Rev 2015;263:192–209. 2015;1:965–74.
12. Fischer U, Forster M, Rinaldi A, et al. Genomics and drug profiling of 32. Stilgenbauer S, Furman RR, Zent CS. Management of chronic
fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies lymphocytic leukemia. Am Soc Clin Oncol Educ Book 2015;164–75.
recurrent mutation patterns and therapeutic options. Nat Genet 33. Dighiero G. Unsolved issues in CLL biology and management. Leukemia
2015;47:1020–9. 2003;17:2385–91.
13. Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating 34. Abou-Nassar K, Brown JR. Novel agents for the treatment of chronic
lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med lymphocytic leukemia. Clin Adv Hematol Oncol 2010;8:886–95.
2014;371:1005–15. 35. Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in
14. Izraeli S. Beyond Philadelphia: ‘Ph-like’ B cell precursor acute previously treated chronic lymphoid leukemia. N Engl J Med
lymphoblastic leukemias - diagnostic challenges and therapeutic 2014;371:213–23.
promises. Curr Opin Hematol 2014;21:289–96. 36. Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as Initial Therapy for
15. Harrison CJ, Haas O, Harbott J, et al. Detection of prognostically relevant Patients with Chronic Lymphocytic Leukemia. N Engl J Med
genetic abnormalities in childhood B-cell precursor acute lymphoblastic 2015;373:2425–37.
leukaemia: recommendations from the Biology and Diagnosis Committee 37. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in
of the International Berlin-Frankfurt-Munster study group. Br J relapsed chronic lymphocytic leukemia. N Engl J Med
Haematol 2010;151:132–42. 2014;370:997–1007.
16. Szczepanski T, Orfao A, van der Velden VH, et al. Minimal residual 38. Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with Venetoclax
disease in leukaemia patients. Lancet Oncol 2001;2:409–17. in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med
17. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to 2016;374:311–22.
treatment redefines all prognostic factors in children and adolescents with 39. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified
B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of T cells in chronic lymphoid leukemia. N Engl J Med 2011;365:725–33.
the AIEOP-BFM ALL 2000 study. Blood 2010;115:3206–14. 40. Scrivener S, Goddard RV, Kaminski ER, et al. Abnormal T-cell function
18. Koch SV, Kejs AM, Engholm G, et al. Leaving home after cancer in in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 2003;
childhood: a measure of social independence in early adulthood. Pediatr 44:383–9.
Blood Cancer 2006;47:61–70. 41. Hamblin TJ. Autoimmune complications of chronic lymphocytic
19. Anderson K, Lutz C, van Delft FW, et al. Genetic variegation of clonal leukemia. Semin Oncol 2006;33:230–9.
architecture and propagating cells in leukaemia. Nature 2011;469:356–61. 42. Goldschmidt N, Gural A, Ben-Yehuda D, et al. Short communication:
20. Klinger M, Benjamin J, Kischel R, et al. Harnessing T cells to fight cancer bendamustine-related hemolytic anemia in chronic lymphocytic
with BiTE(R) antibody constructs–past developments and future leukemia. Cancer Chemother Pharmacol 2013;72:709–13.
directions. Immunol Rev 2016;270:193–208. 43. Rossi D, Gaidano G. Richter syndrome: pathogenesis and management.
21. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing Semin Oncol 2016;43:311–19.
CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in